Se han actualizado los datos del año 2021 y 2022 según el último año disponible en las fuentes oficiales. Es posible que para ciertas variables no se dispongan todavía de datos del año 2022.
Por razones metodológicas, han surgido las siguientes modificaciones:
La patología “Otras infecciones agudas de las vías respiratorias inferiores” se denomina ahora “Bronquitis y bronquiolitis agudas J20-J22”, siguiendo los cambios del INE en base al CIE-10.
Los datos de “renta neta media por persona” tanto a nivel provincia como por Comunidad Autónoma provienen ahora del Atlas, en lugar del INE.
Los datos de “Tasa de Pobreza” e “Índice GINI” de 2019 y 2020 se han actualizado siguiendo cambios metodológicos del INE.
Próximamente se incluirán nuevos indicadores sobre Migraña, Dolor Cervical, Dolor Lumbar, Alergia, Asma, Depresión, Ansiedad Crónica, Ictus y Otros Problemas Mentales Crónicos a nivel Comunidad Autónoma para los años 2014, 2017 y 2020 (a partir de la Encuesta Europea de Salud en España, EESE).
This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.